ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO362

Utilizing a Patient-Specific iPSC Platform for the Study of Rare Genetic Kidney and Vascular Diseases

Session Information

Category: Development‚ Stem Cells‚ and Regenerative Medicine

  • 500 Development‚ Stem Cells‚ and Regenerative Medicine


  • Diatlov, Daniel, University of Toronto Institute of Medical Science, Toronto, Ontario, Canada
  • Melzer, Franz Leonard, The Hospital for Sick Children Research Institute Cell Biology Program, Toronto, Ontario, Canada
  • Bohorquez, Arlette, The Hospital for Sick Children Research Institute Cell Biology Program, Toronto, Ontario, Canada
  • Ma, Alison Lap Tak, Hong Kong Children's Hospital Department of Paediatric Nephrology, Kowloon City, Hong Kong
  • Licht, Christoph, The Hospital for Sick Children Division of Nephrology, Toronto, Ontario, Canada

The increasing use of induced pluripotent stem cells (iPSCs) to model human genetic diseases in vitro has allowed researchers to better understand the pathology of countless disorders, and subsequently develop better treatments for patients. Currently in our lab we use blood-outgrowth endothelial cells (BOECs) to study endothelial cell (EC) dysfunction in kidney diseases and thrombotic microangiopathies. However, isolating patient BOECs is often challenging, as it requires a significant sample of fresh blood which is not always readily available. As such, we are working to utilize a platform that uses patient skin fibroblasts to create patient-specific iPSCs, that can then be differentiated into ECs which capture the genetic conditions of patients.


Patient skin fibroblast-derived iPSCs and healthy control iPSCs were created using a commercially available Sendai virus CytoTune-iPS 2.0 reprogramming kit (Thermo Fisher). These iPSCs were then differentiated into ECs using a directed differentiation protocol in factor-defined media. Following differentiation, CD31 (PECAM1) positive cells were sorted using fluorescence-activated cell sorting (FACS), to isolate a pure population. Isolated ECs were then characterized using immunofluorescence (IF) staining for CD31 and VE-Cadherin, as well as a tubule formation assay.


We were able to successfully create the iPSCs and differentiate them into ECs that express the appropriate markers (CD31 and VE-Cadherin) and are able to successfully form robust capillary-like tubes over a 48 hour period.


Our iPSC differentiation protocol provides a verified and valuable tool for the study of genetic kidney disorders involving endothelial cells when BOEC isolation is not possible.

Figure 1. (A) Patient iPSC ECs sorted for CD31 using FACS express CD31 and VE-Cadherin (20x). (B) Patient iPSC ECs form robust capillary-like tubes over 48 hours (4x).


  • Government Support – Non-U.S.